Septerna (NASDAQ:SEPN) Given New $48.00 Price Target at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its price target raised by investment analysts at Wells Fargo & Company from $28.00 to $48.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 71.94% from the company’s current price.

Several other research analysts also recently weighed in on SEPN. Raymond James Financial began coverage on Septerna in a research note on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target for the company. Truist Financial initiated coverage on shares of Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. JonesTrading began coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target on the stock. Finally, HC Wainwright raised their price objective on shares of Septerna from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Septerna Stock Down 2.5%

Septerna stock traded down $0.72 during trading on Tuesday, hitting $27.92. The stock had a trading volume of 16,859 shares, compared to its average volume of 304,001. The stock’s 50 day moving average is $26.93 and its two-hundred day moving average is $22.54. Septerna has a 1 year low of $4.66 and a 1 year high of $32.63. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -18.49 and a beta of 3.85.

Insiders Place Their Bets

In related news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its stake in Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after buying an additional 1,260,409 shares during the period. First Light Asset Management LLC bought a new stake in shares of Septerna during the 4th quarter valued at about $17,308,000. Primecap Management Co. CA purchased a new position in shares of Septerna during the fourth quarter worth about $15,225,000. Perceptive Advisors LLC bought a new position in shares of Septerna in the second quarter worth approximately $5,723,000. Finally, VR Adviser LLC bought a new position in shares of Septerna in the second quarter worth approximately $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.